Physician profile
Victor Sam Wang
NPI 1285297135
$19,225.42
in general payments reported to CMS, 2019-2025
16 companies · $15K in 2025
The $15K reported for 2025 was more than what 91% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $447 · 2022: $1,055 · 2023: $1,334 · 2024: $1,270 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $3,919 · Consulting Fee: $1,525 · Travel and Lodging: $72.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,206.25 |
| Food and Beverage | $3,918.91 |
| Consulting Fee | $1,525.00 |
| Travel and Lodging | $72.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $11,586.01 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Pfizer INC. | $5,203.18 | 2023-2025 | |
| Lilly USA, LLC | $483.14 | 2021-2025 | Emgality, Amyvid, Reyvow |
| Teva Pharmaceuticals USA, INC. | $470.76 | 2021-2025 | Austedo Xr, Ajovy |
| Biogen, INC. | $450.00 | 2022 | |
| Impel Pharmaceuticals INC. | $226.85 | 2022-2023 | Trudhesa |
| Amgen INC. | $174.22 | 2023-2024 | Aimovig |
| Janssen Biotech, INC. | $144.45 | 2025 | Tremfya, Simponi Aria |
| Biohaven Pharmaceuticals, INC. | $142.05 | 2021 | |
| Immedica Pharma US, INC. | $117.53 | 2023 | |
| Zogenix INC. | $60.04 | 2021 | |
| Amneal Pharmaceuticals LLC | $42.10 | 2025 | Brekiya |
| Eli Lilly and Company | $41.52 | 2022 | |
| Axsome Therapeutics, INC. | $29.00 | 2025 | Symbravo |
| Ipsen Biopharmaceuticals, INC | $27.94 | 2023-2025 | Dysport |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $26.63 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.